{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T22:54:18Z","timestamp":1770764058299,"version":"3.50.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL72299"],"award-info":[{"award-number":["HL72299"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL82889"],"award-info":[{"award-number":["HL82889"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.3816\/clm.2009.s.034","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T06:04:58Z","timestamp":1254204298000},"page":"S347-S356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"S3","title":["New Thrombopoietic Growth Factors"],"prefix":"10.3816","volume":"9","author":[{"given":"David J.","family":"Kuter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.s.034_bib1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000205503","article-title":"Demonstration and some properties of human thrombopoietin in thrombocythaemic sera","volume":"20","author":"Kelemen","year":"1958","journal-title":"Acta Haematol"},{"key":"10.3816\/CLM.2009.s.034_bib2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/stem.5530120606","article-title":"The structure, biology and potential therapeutic applications of recombinant thrombopoietin","volume":"12","author":"Lok","year":"1994","journal-title":"Stem Cells"},{"key":"10.3816\/CLM.2009.s.034_bib3","doi-asserted-by":"crossref","first-page":"11104","DOI":"10.1073\/pnas.91.23.11104","article-title":"The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production","volume":"91","author":"Kuter","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2009.s.034_bib4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/369533a0","article-title":"Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand","volume":"369","author":"de Sauvage","year":"1994","journal-title":"Nature"},{"key":"10.3816\/CLM.2009.s.034_bib5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0092-8674(94)90450-2","article-title":"Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl","volume":"77","author":"Bartley","year":"1994","journal-title":"Cell"},{"key":"10.3816\/CLM.2009.s.034_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/oxfordjournals.jbchem.a124883","article-title":"Purification and characterization of thrombopoietin [erratum appears in: J Biochem (Tokyo) 1996; 119:208]","volume":"118","author":"Kato","year":"1995","journal-title":"J Biochem"},{"key":"10.3816\/CLM.2009.s.034_bib7","first-page":"145","article-title":"The oncogene V-MPL, a putative truncated cytokine receptor which immortalized hematopoietic progenitors","volume":"33","author":"Wendling","year":"1991","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.3816\/CLM.2009.s.034_bib8","first-page":"795","article-title":"Structure and transcription of the genomic locus encoding murine c-Mpl, a receptor for thrombopoietin","volume":"10","author":"Alexander","year":"1995","journal-title":"Oncogene"},{"key":"10.3816\/CLM.2009.s.034_bib9","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.1073\/pnas.91.26.13023","article-title":"Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization","volume":"91","author":"Foster","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2009.s.034_bib10","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1073\/pnas.0308530100","article-title":"Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment","volume":"101","author":"Feese","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2009.s.034_bib11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1084\/jem.183.2.651","article-title":"Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin","volume":"183","author":"de Sauvage","year":"1996","journal-title":"J Exp Med"},{"key":"10.3816\/CLM.2009.s.034_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood.V97.1.139","article-title":"c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia","volume":"97","author":"Ballmaier","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib13","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib14","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","article-title":"Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor","volume":"99","author":"Basser","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood.V94.1.365.413a46_365_367","article-title":"Deletion of the extracellular membranedistal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding","volume":"94","author":"Sabath","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib16","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2006-10-019315","article-title":"New thrombopoietic growth factors","volume":"109","author":"Kuter","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0609.2007.00999.x","article-title":"New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura","volume":"69","author":"Kuter","year":"2008","journal-title":"Eur J Haematol Suppl"},{"key":"10.3816\/CLM.2009.s.034_bib18","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood.V100.10.3457","article-title":"Recombinant human thrombopoietin: basic biology and evaluation of clinical studies","volume":"100","author":"Kuter","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199809103391107","article-title":"Thrombopoietin","volume":"339","author":"Kaushansky","year":"1998","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.034_bib20","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood.V89.6.1896","article-title":"Human platelets display high-affinity receptors for thrombopoietin","volume":"89","author":"Broudy","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib21","first-page":"545a","article-title":"Analysis of the thrombopoietin receptor (MPL) on platelets from normal and essential thrombocythemic (ET) patients","volume":"88","author":"Li","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib22","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.exphem.2008.02.012","article-title":"Transcriptional regulation of bone marrow thrombopoietin by platelet proteins","volume":"36","author":"McIntosh","year":"2008","journal-title":"Exp Hematol"},{"key":"10.3816\/CLM.2009.s.034_bib23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood.V88.2.511.bloodjournal882511","article-title":"Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates","volume":"88","author":"Harker","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/stem.160375","article-title":"The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation","volume":"16","author":"Wagemaker","year":"1998","journal-title":"Stem Cells"},{"key":"10.3816\/CLM.2009.s.034_bib25","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1182\/blood.V86.12.4486.bloodjournal86124486","article-title":"Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice","volume":"86","author":"Hokom","year":"1995","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib26","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1182\/blood.V90.11.4369","article-title":"High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice","volume":"90","author":"Villeval","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.V88.2.402.bloodjournal882402","article-title":"A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation","volume":"88","author":"Yan","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4049\/jimmunol.160.2.691","article-title":"Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis","volume":"160","author":"Frey","year":"1998","journal-title":"J Immunol"},{"key":"10.3816\/CLM.2009.s.034_bib29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1056\/NEJM199702063360603","article-title":"Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer","volume":"336","author":"Fanucchi","year":"1997","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.034_bib30","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(96)04471-6","article-title":"Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer","volume":"348","author":"Basser","year":"1996","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.034_bib31","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood.V87.5.1833.1833","article-title":"Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates","volume":"87","author":"Harker","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib32","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLM.2009.s.034_bib33","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2003.08.003","article-title":"Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia","volume":"21","author":"Vadhan-Raj","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.034_bib34","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood.V93.9.2798","volume":"93","author":"Somlo","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1083-8791(00)70049-8","article-title":"A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation","volume":"6","author":"Nash","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.034_bib36","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood.V95.8.2530","article-title":"A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia","volume":"95","author":"Schiffer","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib37","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/blood.V100.2.728","article-title":"Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura","volume":"100","author":"Nomura","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib38","first-page":"296a","article-title":"Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (plt) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS)","volume":"96","author":"Komatsu","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib39","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1182\/blood.V98.5.1339","article-title":"Thrombopoietin therapy increases platelet yields in healthy platelet donors","volume":"98","author":"Kuter","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib40","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood.V98.5.1346","article-title":"Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin","volume":"98","author":"Goodnough","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib41","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/S0140-6736(02)09090-6","article-title":"Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study","volume":"359","author":"Vadhan-Raj","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.034_bib42","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1126\/science.276.5319.1696","article-title":"Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine","volume":"276","author":"Cwirla","year":"1997","journal-title":"Science"},{"key":"10.3816\/CLM.2009.s.034_bib43","doi-asserted-by":"crossref","first-page":"363a","DOI":"10.1182\/blood.V106.11.1249.1249","article-title":"Stimulation of platelet production in healthy volunteers by a novel pegylated peptide-based thrombopoietin (TPO) receptor agonist","volume":"106","author":"Cerneus","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib44","doi-asserted-by":"crossref","first-page":"14307","DOI":"10.1073\/pnas.0602658103","article-title":"A rationally designed agonist antibody fragment that functionally mimics thrombopoietin","volume":"103","author":"Frederickson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2009.s.034_bib45","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.034_bib46","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","article-title":"Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand","volume":"76","author":"Wang","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.3816\/CLM.2009.s.034_bib47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2003.05.001","article-title":"AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl","volume":"25","author":"Broudy","year":"2004","journal-title":"Cytokine"},{"key":"10.3816\/CLM.2009.s.034_bib48","doi-asserted-by":"crossref","first-page":"1171a","DOI":"10.1182\/blood.V112.11.3416.3416","article-title":"Evaluation of bone marrow reticulin formation in romiplostim-treated adult patients with chronic ITP","volume":"112","author":"Kuter","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.034_bib50","author":"US Food and Drug Administration"},{"key":"10.3816\/CLM.2009.s.034_bib51","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1021\/jm010283l","article-title":"Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis","volume":"44","author":"Duffy","year":"2001","journal-title":"J Med Chem"},{"key":"10.3816\/CLM.2009.s.034_bib52","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1021\/jm0255365","article-title":"Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics","volume":"45","author":"Duffy","year":"2002","journal-title":"J Med Chem"},{"key":"10.3816\/CLM.2009.s.034_bib53","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","article-title":"Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist","volume":"109","author":"Jenkins","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib54","doi-asserted-by":"crossref","first-page":"145a","DOI":"10.1182\/blood.V108.11.477.477","article-title":"Single and multiple oral doses of AKR-501 (TM477) increase the platelet count in healthy volunteers","volume":"108","author":"Desjardins","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib55","doi-asserted-by":"crossref","first-page":"390a","DOI":"10.1182\/blood.V110.11.1298.1298","article-title":"Single and multiple oral doses of LGD-4665, a small molecule thrombopoietin receptor agonist, increase platelet counts in healthy male subjects","volume":"110","author":"Dziewanowska","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib56","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1182\/blood-2005-11-4433","article-title":"A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis","volume":"107","author":"Nakamura","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib57","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.12752","article-title":"The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis","volume":"93","author":"Nogami","year":"2008","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.034_bib58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2008.02.060","article-title":"Characterization of novel non-peptide thrombopoietin mimetics, their species specificity and the activation mechanism of the thrombopoietin receptor","volume":"586","author":"Yamane","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.3816\/CLM.2009.s.034_bib59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1042\/BSR20080086","article-title":"Discovery of novel non-peptide thrombopoietin mimetic compounds that induce megakaryocytopoiesis","volume":"28","author":"Yamane","year":"2008","journal-title":"Biosci Rep"},{"key":"10.3816\/CLM.2009.s.034_bib60","doi-asserted-by":"crossref","first-page":"795a","DOI":"10.1182\/blood.V104.11.2909.2909","article-title":"Species specificity and receptor domain interaction of a small molecule TPO receptor agonist","volume":"104","author":"Erickson-Miller","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib61","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.exphem.2008.04.020","article-title":"AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis","volume":"36","author":"Fukushima-Shintani","year":"2008","journal-title":"Exp Hematol"},{"key":"10.3816\/CLM.2009.s.034_bib62","doi-asserted-by":"crossref","first-page":"797a","DOI":"10.1182\/blood.V104.11.2916.2916","article-title":"An oral, non-peptide, small molecule thrombopoietin receptor agonist increases platelet counts in healthy subjects","volume":"104","author":"Jenkins","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib63","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.034_bib64","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0609.2008.01198.x","article-title":"AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist","volume":"82","author":"Fukushima-Shintani","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2009.s.034_bib65","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1182\/blood-2004-04-1482","article-title":"A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor","volume":"105","author":"Orita","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib66","doi-asserted-by":"crossref","first-page":"336a","DOI":"10.1182\/blood.V108.11.1134.1134","article-title":"Domain subclass conversion improved activity of anti-Mpl agonist antibodies in the form of whole IgG","volume":"108","author":"Kai","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib67","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-2141.2005.05542.x","article-title":"Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura","volume":"129","author":"Rajan","year":"2005","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.034_bib68","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMoa073255","article-title":"Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C","volume":"357","author":"McHutchison","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.034_bib69","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1172\/JCI106077","article-title":"Thrombokinetics in man","volume":"48","author":"Harker","year":"1969","journal-title":"J Clin Invest"},{"key":"10.3816\/CLM.2009.s.034_bib70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1172\/JCI113060","article-title":"Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance","volume":"80","author":"Ballem","year":"1987","journal-title":"J Clin Invest"},{"key":"10.3816\/CLM.2009.s.034_bib71","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood-2003-08-2672","article-title":"Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP","volume":"103","author":"McMillan","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib72","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2003-01-0275","article-title":"Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura","volume":"103","author":"Houwerzijl","year":"2004","journal-title":"Blood"},{"issue":"suppl 2","key":"10.3816\/CLM.2009.s.034_bib73","first-page":"425","article-title":"Efficacy and safety of romiplostim versus standard of care as chronic therapy for nonsplenectomized patients with immune thrombocytopenia (ITP)","volume":"94","author":"Rummel","year":"2009","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.034_bib74","doi-asserted-by":"crossref","first-page":"174a","DOI":"10.1182\/blood.V110.11.568.568","article-title":"Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 2-year update","volume":"110","author":"Bussel","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib75","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with ITP [erratum appears in Blood 2009; 113:4822]","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib76","doi-asserted-by":"crossref","first-page":"154a","DOI":"10.1182\/blood.V112.11.402.402","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenic purpura (ITP): 3-year update from an open-label extension study","volume":"112","author":"Kuter","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"10.3816\/CLM.2009.s.034_bib77","first-page":"377","article-title":"Evaluating the long-term efficacy of romiplostim (AMG 531) in patients with chronic immune thrombocytopenic purpura (ITP) during an open-label extension study","volume":"93","author":"Newland","year":"2008","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.034_bib78","doi-asserted-by":"crossref","first-page":"153a","DOI":"10.1182\/blood.V112.11.400.400","article-title":"Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: Results of a phase III, double-blind, placebo-controlled study (RAISE)","volume":"112","author":"Cheng","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib79","doi-asserted-by":"crossref","first-page":"1177a","DOI":"10.1182\/blood.V112.11.3432.3432","article-title":"Safety and efficacy of long-term treatment with oral eltrombopag for chronic ITP","volume":"112","author":"Bussel","year":"2008","journal-title":"Blood"},{"issue":"18 suppl","key":"10.3816\/CLM.2009.s.034_bib80","first-page":"365a","article-title":"Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): Preliminary results of a phase 1\/2 study","volume":"25","author":"Kantarjian","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.034_bib81","doi-asserted-by":"crossref","first-page":"81a","DOI":"10.1182\/blood.V110.11.250.250","article-title":"Phase 1\/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): Update including extended treatment","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib82","doi-asserted-by":"crossref","first-page":"89a","DOI":"10.1182\/blood.V112.11.224.224","article-title":"Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.034_bib83","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2007.06807.x","article-title":"Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres","volume":"139","author":"Kuter","year":"2007","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.034_bib84","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1309\/09NP-3DFG-BLM9-E5LE","article-title":"Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders","volume":"117","author":"Douglas","year":"2002","journal-title":"Am J Clin Pathol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:19:23Z","timestamp":1761563963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":84,"alternative-id":["S1557919011703626"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.s.034","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Thrombopoietic Growth Factors","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma and Myeloma","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLM.2009.s.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}